Formulation of controlled-release baclofen matrix tablets. II. Influence of some hydrophobic excipients on the release rate and in vitro evaluation. (25/85)

 (+info)

Metabolic engineering of hydroxy fatty acid production in plants: RcDGAT2 drives dramatic increases in ricinoleate levels in seed oil. (26/85)

 (+info)

Regulatory monoubiquitination of phosphoenolpyruvate carboxylase in germinating castor oil seeds. (27/85)

 (+info)

Acoustic pressure wound therapy in the treatment of stage II pressure ulcers. (28/85)

Pressure ulcers are localized skin injuries secondary to unrelieved pressure or friction. Patients with immobility issues are at increased risk for developing pressure ulcers. In 2004, stricter federal regulations for prevention and treatment of pressure ulcers in institutional settings--eg, long-term care facilities--were introduced. Effective, low-cost treatments for pressure ulcers are needed; acoustic pressure wound therapy (APWT), a noncontact, low-frequency, therapeutic ultrasound system, is one option. A retrospective case series of six long-term care patients (two men and one woman, age range 61 to 92 years), each with one Stage II pressure ulcer, is presented. Acoustic pressure wound therapy was provided as an adjunct to standard treatment that included balsam of Peru/castor oil/trypsin ointment, hydrogel, hydrocolloid dressings, silver dressings, and offloading. Outcomes (days to healing) were determined through changes in wound dimensions. Study participants each received APWT for 3 to 4 minutes three to four times weekly. In four of the six wounds, the average number of days to healing was 22. One of the two remaining patients discontinued treatment at 95% healed; treatment for the sixth patient was ongoing due to hospitalization that delayed APWT. In a long-term care setting, APWT added to standard of care may accelerate healing of Stage II pressure ulcers.  (+info)

Bone regeneration after demineralized bone matrix and castor oil (Ricinus communis) polyurethane implantation. (29/85)

 (+info)

Improving tenoxicam solubility and bioavailability by cosolvent system. (30/85)

 (+info)

Antidiarrhoeal activity of Psidium guajava Linn. (Myrtaceae) leaf aqueous extract in rodents. (31/85)

The leaf of Psidium guajava Linn. (family: Myrtaceae) is used traditionally in African folk medicine to manage, control and/or treat a plethora of human ailments, including diarrhoea. In this study, we examined the antidiarrhoeal activity of Psidium guajava leaf aqueous extract (PGE) on experimentally-induced diarrhoea in rodents. PGE (50-400 mg/kg p.o.) produced dose-dependent and significant (P<0.05-0.01) protection of rats and mice against castor oil-induced diarrhoea, inhibited intestinal transit, and delayed gastric emptying. Like atropine (1 mg/kg, p.o.), PGE produced dose-dependent and significant (P<0.05-0.01) antimotility effect, and caused dose-related inhibition of castor oil-induced enteropooling in the animals. Like loperamide (10 mg/kg, p.o.), PGE dose-dependently and significantly (P<0.05-0.01) delayed the onset of castor oil-induced diarrhoea, decreased the frequency of defaecation, and reduced the severity of diarrhoea in the rodents. Compared with control animals, PGE dose-dependently and significantly (P<0.05-0.01) decreased the volume of castor oil-induced intestinal fluid secretion, and reduced the number, weight and wetness of faecal droppings. PGE also produced concentration-related and significant (P<0.05-0.01) inhibitions of the spontaneous, rhythmic, pendular contractions of the rabbit isolated duodenum. The findings of this study indicate that PGE possesses antidiarrhoeal activity, and thus lend pharmacological credence to the suggested folkloric use of the plant as a natural remedy for the treatment, management and/or control of diarrhoea in some rural communities of southern Africa.  (+info)

Preparation and evaluation of self-nanoemulsifying tablets of carvedilol. (32/85)

 (+info)